LSI Segment Divestment

Mid-Term Guidance 2023 Double-digit sales growth per year driven by Biologics, Small Molecules and Cell & Gene Therapy businesses Double-digit sales growth per year - 33% - 35% CORE EBITDA margin Improved CORE EBITDA margin despite investments in growth projects Double-digit ROIC driven by growth and margin expansion Double-digit ROIC CORE definition: See appendix 34

View entire presentation